Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Holden Comprehensive Cancer Center at University of Iowa
1047
mi
from 02139
Iowa City, IA
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Holden Comprehensive Cancer Center at University of Iowa
1047
mi
from 02139
Iowa City, IA
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Lahey Clinic Medical Center - Burlington
10
mi
from 02139
Burlington, MA
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Lahey Clinic Medical Center - Burlington
10
mi
from 02139
Burlington, MA
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Blodgett Hospital at Spectrum Health
737
mi
from 02139
Grand Rapids, MI
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Blodgett Hospital at Spectrum Health
737
mi
from 02139
Grand Rapids, MI
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Cancer Center
1079
mi
from 02139
Rochester, MN
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Cancer Center
1079
mi
from 02139
Rochester, MN
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Boone Hospital Center
1132
mi
from 02139
Columbia, MO
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Boone Hospital Center
1132
mi
from 02139
Columbia, MO
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Overlook Hospital
203
mi
from 02139
Summit, NJ
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Overlook Hospital
203
mi
from 02139
Summit, NJ
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Stony Brook University Cancer Center
127
mi
from 02139
Stony Brook, NY
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Stony Brook University Cancer Center
127
mi
from 02139
Stony Brook, NY
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
SUNY Upstate Medical University Hospital
259
mi
from 02139
Syracuse, NY
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
SUNY Upstate Medical University Hospital
259
mi
from 02139
Syracuse, NY
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Duke Cancer Institute
605
mi
from 02139
Durham, NC
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Duke Cancer Institute
605
mi
from 02139
Durham, NC
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Center
544
mi
from 02139
Cleveland, OH
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Center
544
mi
from 02139
Cleveland, OH
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
INTEGRIS Cancer Institute of Oklahoma - Proton Campus
1492
mi
from 02139
Oklahoma City, OK
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
INTEGRIS Cancer Institute of Oklahoma - Proton Campus
1492
mi
from 02139
Oklahoma City, OK
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Providence Cancer Center at Providence Portland Medical Center
2526
mi
from 02139
Portland, OR
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Center at Providence Portland Medical Center
2526
mi
from 02139
Portland, OR
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Forbes Regional Hospital
468
mi
from 02139
Monroeville, PA
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Forbes Regional Hospital
468
mi
from 02139
Monroeville, PA
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Allegheny Cancer Center at Allegheny General Hospital
479
mi
from 02139
Pittsburgh, PA
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Allegheny Cancer Center at Allegheny General Hospital
479
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
476
mi
from 02139
Pittsburgh, PA
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
476
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Lankenau Cancer Center at Lankenau Hospital
271
mi
from 02139
Wynnewood, PA
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Lankenau Cancer Center at Lankenau Hospital
271
mi
from 02139
Wynnewood, PA
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin Cancer Center
859
mi
from 02139
Milwaukee, WI
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin Cancer Center
859
mi
from 02139
Milwaukee, WI
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
1036
mi
from 02139
Saint Louis, MO
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
1036
mi
from 02139
Saint Louis, MO
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
184
mi
from 02139
New York, NY
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
184
mi
from 02139
New York, NY
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
M. D. Anderson Cancer Center at University of Texas
1605
mi
from 02139
Houston, TX
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
M. D. Anderson Cancer Center at University of Texas
1605
mi
from 02139
Houston, TX
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
929
mi
from 02139
Madison, WI
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
929
mi
from 02139
Madison, WI
Click here to add this to my saved trials
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
St. Paul's Hospital at Providence Health Care - Vancouver
2498
mi
from 02139
Vancouver,
Laparoscopic-Assisted Resection or Open Resection in Treating Patients With Rectal Cancer
A Phase III Prospective Randomized Trial Comparing Laparoscopic-Assisted Resection Versus Open Resection for Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
St. Paul's Hospital at Providence Health Care - Vancouver
2498
mi
from 02139
Vancouver,
Click here to add this to my saved trials
Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Study of the MUC1 Peptide - Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Status: Enrolling
Updated:  12/31/1969
Digestive Disorders Clinic
477
mi
from 02139
Pittsburgh, PA
Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Study of the MUC1 Peptide - Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Status: Enrolling
Updated: 12/31/1969
Digestive Disorders Clinic
477
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
390
mi
from 02139
Bethesda, MD
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Medical Center
2538
mi
from 02139
Loma Linda, CA
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Medical Center
2538
mi
from 02139
Loma Linda, CA
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
St. Joseph Hospital
2578
mi
from 02139
Orange, CA
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
St. Joseph Hospital
2578
mi
from 02139
Orange, CA
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente-San Diego
2569
mi
from 02139
San Diego, CA
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente-San Diego
2569
mi
from 02139
San Diego, CA
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Medical Center - Vallejo
2671
mi
from 02139
Vallejo, CA
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Medical Center - Vallejo
2671
mi
from 02139
Vallejo, CA
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
CCOP - Christiana Care Health Services
304
mi
from 02139
Newark, DE
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
CCOP - Christiana Care Health Services
304
mi
from 02139
Newark, DE
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center at Orlando
1115
mi
from 02139
Orlando, FL
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center at Orlando
1115
mi
from 02139
Orlando, FL
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
CCOP - NorthShore University HealthSystem
848
mi
from 02139
Evanston, IL
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
CCOP - NorthShore University HealthSystem
848
mi
from 02139
Evanston, IL
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
Edward Hospital
870
mi
from 02139
Naperville, IL
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
Edward Hospital
870
mi
from 02139
Naperville, IL
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
University of Iowa
1048
mi
from 02139
Iowa City, IA
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
University of Iowa
1048
mi
from 02139
Iowa City, IA
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
NortonHealthcare, Inc.
821
mi
from 02139
Louisville, KY
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
NortonHealthcare, Inc.
821
mi
from 02139
Louisville, KY
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
Franklin Square Hospital Center
351
mi
from 02139
Baltimore, MD
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
Franklin Square Hospital Center
351
mi
from 02139
Baltimore, MD
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
CCOP - Grand Rapids Clinical Oncology Program
739
mi
from 02139
Grand Rapids, MI
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
CCOP - Grand Rapids Clinical Oncology Program
739
mi
from 02139
Grand Rapids, MI
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
CCOP, William Beaumont Hospital
614
mi
from 02139
Royal Oak, MI
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
CCOP, William Beaumont Hospital
614
mi
from 02139
Royal Oak, MI
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
CCOP, Dayton, OH
704
mi
from 02139
Dayton, OH
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
CCOP, Dayton, OH
704
mi
from 02139
Dayton, OH
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Hospital
268
mi
from 02139
Philadelphia, PA
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Hospital
268
mi
from 02139
Philadelphia, PA
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
NSABP Foundation, Inc.
479
mi
from 02139
Pittsburgh, PA
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
NSABP Foundation, Inc.
479
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
Allegheny Cancer Center at Allegheny General Hospital
479
mi
from 02139
Pittsburgh, PA
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
Allegheny Cancer Center at Allegheny General Hospital
479
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
477
mi
from 02139
Pittsburgh, PA
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
477
mi
from 02139
Pittsburgh, PA
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
Vermont Cancer Center at University of Vermont
180
mi
from 02139
Burlington, VT
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
Vermont Cancer Center at University of Vermont
180
mi
from 02139
Burlington, VT
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin
853
mi
from 02139
Milwaukee, WI
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin
853
mi
from 02139
Milwaukee, WI
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
610
mi
from 02139
Detroit, MI
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
610
mi
from 02139
Detroit, MI
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
CCOP - Metro-Minnesota
1122
mi
from 02139
Saint Louis Park, MN
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
CCOP - Metro-Minnesota
1122
mi
from 02139
Saint Louis Park, MN
Click here to add this to my saved trials
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated:  12/31/1969
CCOP - Upstate Carolina
775
mi
from 02139
Spartanburg, SC
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver
Status: Enrolling
Updated: 12/31/1969
CCOP - Upstate Carolina
775
mi
from 02139
Spartanburg, SC
Click here to add this to my saved trials
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1763
mi
from 02139
Denver, CO
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1763
mi
from 02139
Denver, CO
Click here to add this to my saved trials
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
357
mi
from 02139
Baltimore, MD
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
357
mi
from 02139
Baltimore, MD
Click here to add this to my saved trials
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1965
mi
from 02139
Albuquerque, NM
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1965
mi
from 02139
Albuquerque, NM
Click here to add this to my saved trials